Therefore, this study found that the combination of vitexin and aspirin inhibited the expression of NF-κB in colorectal cancer HT-29 cells more significantly than that of a single drug, suggesting that the novel combined anticancer activity with a focus on colorectal carcinoma effect of vitexin and aspirin may be achieved by inhibiting NF-κB activity and thus COX-2 expression. Here, PTGS2 is linked to colorectal cancer.